Fayl-Billot, France

Daniel Boccio


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Pringy, FR (2006)
  • Fayl-Billot, FR (2007)

Company Filing History:


Years Active: 2006-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel Boccio

Introduction

Daniel Boccio is a notable inventor based in Fayl-Billot, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Parkinson's disease. With a total of 2 patents, Boccio's work focuses on innovative combinations of compounds that target specific neurological pathways.

Latest Patents

Boccio's latest patents include a groundbreaking invention that combines a CB1 receptor antagonist with a product that activates dopaminergic neurotransmission in the brain. This combination aims to enhance the treatment options available for Parkinson's disease. The invention details the use of one or more CB1 antagonist azetidine derivatives alongside products that stimulate dopaminergic activity, leading to potential advancements in therapeutic approaches for this debilitating condition.

Career Highlights

Daniel Boccio is currently associated with Aventis Pharma S.A., where he continues to develop and refine his innovative ideas. His work at the company has positioned him as a key player in the pharmaceutical industry, particularly in the realm of neurological treatments.

Collaborations

Boccio collaborates with esteemed colleagues such as Jésus Benavides and Yvette Henin. Their combined expertise fosters a productive environment for research and development, enhancing the potential for groundbreaking discoveries in their field.

Conclusion

In summary, Daniel Boccio's contributions to pharmaceutical innovations, particularly in the treatment of Parkinson's disease, highlight his role as a significant inventor. His work continues to pave the way for new therapeutic strategies that could improve the lives of many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…